C. Binkert

发表

Design and preparation of potent, nonpeptidic, bioavailable renin inhibitors.

L. Prade, A. Treiber, S. Delahaye, 2009, Journal of medicinal chemistry.

New classes of potent and bioavailable human renin inhibitors.

L. Prade, A. Treiber, S. Delahaye, 2009, Bioorganic & medicinal chemistry letters.

Inhibitors of Plasmepsin II-potential antimalarial agents.

L. Prade, G. Dunet, R. Brun, 2004, Bioorganic & medicinal chemistry letters.

The versican C-type lectin domain recognizes the adhesion protein tenascin-R.

E. Ruoslahti, A. Aspberg, C. Binkert, 1995, Proceedings of the National Academy of Sciences of the United States of America.

Pharmacology of the Urotensin-II Receptor Antagonist ACT-058362: First Demonstration of a Pathophysiological Role of the Urotensin System

M. Clozel, O. Nayler, M. Scherz, 2004 .

Pharmacology of the Urotensin-II Receptor Antagonist Palosuran (ACT-058362; 1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea Sulfate Salt): First Demonstration of a Pathophysiological Role of the Urotensin System

M. Clozel, O. Nayler, M. Scherz, 2004, Journal of Pharmacology and Experimental Therapeutics.

The Expression of Urotensin II Receptor (U2R) is Up‐regulated by Interferon‐γ

O. Nayler, C. Binkert, Magdalena Birker-Robaczewska, 2003, Journal of receptor and signal transduction research.

HypertensionFactor of Pulmonary Arterial Endothelin-1/Endothelin-3 Ratio: A Potential

R. Souza, M. Montani, M. Clozel, 2007 .

Endothelin-1/endothelin-3 ratio: a potential prognostic factor of pulmonary arterial hypertension.

M. Humbert, G. Simonneau, D. Montani, 2007, Chest.

Constitutive expression of murine Sak-a suppresses cell growth and induces multinucleation

J. Dennis, C. Binkert, C. Fode, 1996, Molecular and cellular biology.

Bosentan, Sildenafil, and Their Combination in the Monocrotaline Model of Pulmonary Hypertension in Rats

M. Iglarz, M. Clozel, P. Hess, 2006, Experimental biology and medicine.

Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist

M. Bolli, M. Iglarz, M. Clozel, 2008, Journal of Pharmacology and Experimental Therapeutics.

The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist.

M. Bolli, M. Iglarz, M. Clozel, 2012, Journal of medicinal chemistry.

Influence of Acute and Chronic Mineralocorticoid Excess on Endothelial Function in Healthy Men

F. Nietlispach, H. Brunner-La Rocca, W. Kiowski, 2007, Hypertension.

Structure of the human insulin-like growth factor binding protein-2 gene.

J. Schwander, G. Heinrich, C. Binkert, 1992, Molecular endocrinology.

Recombinant human [Cys281]insulin-like growth factor-binding protein 2 inhibits both basal and insulin-like growth factor I-stimulated proliferation and collagen synthesis in fetal rat calvariae.

D. B. Evans, S. Geisse, J. Feyen, 1991, The Journal of biological chemistry.

Characterization of a stable, hypertensive rat model suitable for the consecutive evaluation of human renin inhibitors

M. Percival, D. Riendeau, W. Cromlish, 2011, Journal of the renin-angiotensin-aldosterone system : JRAAS.

Novel benzo[1,4]diazepin-2-one derivatives as endothelin receptor antagonists.

J. Marfurt, M. Bolli, É. Thorin, 2004, Journal of medicinal chemistry.

Regulation of Osteogenesis by Fetuin*

Howard C. Tenenbaum, J. Dennis, M. Demetriou, 1999, The Journal of Biological Chemistry.

A new class of inhibitors for the malarial aspartic protease plasmepsin II based on a central 11-azatricyclo[6.2.1.02,7]undeca-2,4,6-triene scaffold

F. Diederich, H. Märki, A. Dorn, 2003 .

Development of a New Class of Inhibitors for the Malarial Aspartic Protease Plasmepsin II Based on a Central 7‐Azabicyclo[2.2.1]heptane Scaffold

F. Diederich, H. Märki, P. Seiler, 2003 .

Clinical pharmacology of single‐ and multiple‐ascending doses of ACT‐178882, a new direct renin inhibitor, and its pharmacokinetic interaction with food and midazolam

J. Dingemanse, C. Binkert, L. Nicolas, 2013, Fundamental & clinical pharmacology.

Entry-into-humans study with a new direct renin inhibitor

J. Dingemanse, C. Binkert, L. Nicolas, 2012, European Journal of Clinical Pharmacology.

Novel in vivo active anti-malarials based on a hydroxy-ethyl-amine scaffold.

R. de Kanter, S. Wittlin, C. Boss, 2013, Bioorganic & medicinal chemistry letters.

2-imino-thiazolidin-4-one derivatives as potent, orally active S1P1 receptor agonists.

M. Bolli, Stefan Abele, A. Treiber, 2010, Journal of medicinal chemistry.

Replacement of Isobutyl by Trifluoromethyl in Pepstatin A Selectively Affects Inhibition of Aspartic Proteinases

L. Prade, M. Zanda, C. Binkert, 2006, Chembiochem : a European journal of chemical biology.

X-ray Structure of Plasmepsin II Complexed with a Potent Achiral Inhibitor*

L. Prade, D. Bur, S. Richard-Bildstein, 2005, Journal of Biological Chemistry.

Identification of non-peptidic neuromedin U receptor modulators by a robust homogeneous screening assay

H. Su, Ming-Wei Wang, T. Meng, 2008, Acta Pharmacologica Sinica.

A low molecular weight insulin-like growth factor binding protein from rat: cDNA cloning and tissue distribution of its messenger RNA.

Christopher C. Binkert, J. Mary, J. Schwander, 1989, Molecular endocrinology.

Fetuin/α2-HS Glycoprotein Is a Transforming Growth Factor-β Type II Receptor Mimic and Cytokine Antagonist*

Howard C. Tenenbaum, J. Dennis, M. Demetriou, 1996, The Journal of Biological Chemistry.

Cloning, sequence analysis and expression of a cDNA encoding a novel insulin‐like growth factor binding protein (IGFBP‐2).

Christopher C. Binkert, J. Schwander, G. Heinrich, 1989, The EMBO journal.

Insulin-Like Growth Factor-Binding Protein

J. Schwander, G. Heinrich, C. Binkert, 1989, Definitions.

Structure of the human insulin-like growth factor binding protein-2 gene.

J. Schwander, G. Heinrich, C. Binkert, 1992, Molecular endocrinology.

Sak kinase gene structure and transcriptional regulation.

J. Dennis, J. Hudson, L. Chen, 2000, Gene.

Inhibitors of the Plasmodium falciparum parasite aspartic protease plasmepsin II as potential antimalarial agents.

S. Meyer, W. Fischli, S. Richard-Bildstein, 2003, Current medicinal chemistry.

Development of a homogeneous immunoassay for the detection of angiotensin I in plasma using AlphaLISA acceptor beads technology.

J. Falgueyret, M. Percival, Steve Rowland, 2009, Analytical biochemistry.

Tamoxifen attenuates glucocorticoid actions on bone formation in vitro.

Howard C. Tenenbaum, C. McCulloch, R. Zohar, 1997, Endocrinology.

UV-triggered Affinity Capture Identifies Interactions between the Plasmodium falciparum Multidrug Resistance Protein 1 (PfMDR1) and Antimalarial Agents in Live Parasitized Cells*

P. Roepe, D. Fidock, M. Akabas, 2013, The Journal of Biological Chemistry.

Identification of a new chemical class of antimalarials.

Zbynek Bozdech, R. Brun, M. Kaiser, 2012, The Journal of infectious diseases.

Distribution of neuromedin U binding sites in the rat CNS revealed by in vitro receptor autoradiography

C. Binkert, I. Ksiazek, S. Yun, 2008, Neuropeptides.

heart failure and cachexia Cardiac gene expression profile in rats with terminal

M. Lalowski, M. Orešič, M. Baumann, 2015 .

Discovery and Characterization of ACT‐451840: an Antimalarial Drug with a Novel Mechanism of Action

R. Brun, S. Delahaye, S. Wittlin, 2016, ChemMedChem.

De Novo Design, Synthesis, and In Vitro Evaluation of a New Class of Nonpeptidic Inhibitors of the Malarial Enzyme Plasmepsin II

F. Diederich, H. Märki, A. Dorn, 2002, Chembiochem : a European journal of chemical biology.

Characterization of Novel Antimalarial Compound ACT-451840: Preclinical Assessment of Activity and Dose–Efficacy Modeling

R. Price, D. Fidock, R. Sinden, 2016, PLoS medicine.

Pharmacokinetics, Pharmacodynamics, and Tolerability of ACT-077825, a New Direct Renin Inhibitor After Multiple-ascending Doses in Healthy Subjects

J. Dingemanse, C. Binkert, L. Nicolas, 2013, Journal of cardiovascular pharmacology.